ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - repaglinide - טבליה - repaglinide 0.5 mg - repaglinide - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - repaglinide - טבליה - repaglinide 1 mg - repaglinide - repaglinide - treatment of type ii diabetes .

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - repaglinide - טבליה - repaglinide 2 mg - repaglinide - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 1500 iu / 4 ml - coagulation factor viii

ישראל - עברית - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 250 iu / 4 ml - coagulation factor viii

ישראל - עברית - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 3000 iu / 4 ml - coagulation factor viii

ישראל - עברית - Ministry of Health

נובו נורדיסק בע"מ - כלל האוכלוסיה - מחטים להזרקה לשימוש עם עטי: אינסולין, לירגלוטייד, והורמון גדילה של נובו נורדיסק